u/honest_syringe_pls

Correction: that is a tailing factor, not a plate count. Different diagnostics for different problems.

The endpoint vocabulary, because you cannot read this literature without it.

Resolution of steatohepatitis without worsening of fibrosis and improvement in fibrosis without worsening of steatohepatitis are the two standard composite endpoints, both scored on biopsy by pathologists against a defined system. Liver fat fraction is an imaging surrogate that correlates imperfectly with histology.

A trial can move the surrogate substantially and the histological endpoint modestly. Both results are real; they answer different questions. Anybody quoting a response rate here should say which endpoint it refers to, and most summaries do not.

214nm sees the peptide bond, 280nm sees the aromatics

Small fix — 214nm, not 210. It matters for the comparison you are making with the other run.

Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.

Where did the time actually go — international leg, clearance, or last mile?

Chased a ghost peak for three weeks. It was the plumbing. It is always the plumbing.

Correction: those two entries are 3 weeks apart, not consecutive, which changes how the middle of that series reads.

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

Agreed that consistent conditions matter more than frequency. Daily weights under varying conditions are noise.

Push back: comparing a July transit with a February one on the same lane is not a comparison.

Same lane, four orders, 5 to 7 days, all four within a couple of days of the quote. That consistency is the actual finding.

That is area percent, not mass percent. The trace cannot give you the second one.

What wavelength, and what was the gradient?

Correcting myself upthread: I said the gradient was linear and looking again it has a hold in the middle.

What wavelength, and what was the gradient?

How old is the column and roughly how many injections has it seen?

Same method at both labs, or two different gradients?

Agreed. Two analysts, one trace, two integration choices, and a spread that has nothing to do with the vial.

log what you did, not what you meant to do

Gave the same trace to two people I trust and got two integrations about a point apart. That was the most educational afternoon I have had here.

I would not read a single slow shipment as a lane change. Post it and let the median move if it is real.

Push back: the evidence here is phase 2, in a specific population, and it does not support a general ranking.

Are you reading the publication or a summary?

Is that a weight number from a different programme?

the hepatic data is what makes this compound different from the others

Packaging is assessable on arrival with no equipment: rigid outer, no movement inside, the cold element sized to the transit rather than to the box.

Chased a ghost peak for three weeks. It was the plumbing. It is always the plumbing.

Agreed on rigid packaging. It costs the shipper almost nothing and it predicts a lot about the rest of the operation.

a blank injection between samples costs four minutes and settles most arguments

baseline choice is a decision, not a measurement